The Internet of Things revolution for medical devices is here. And, not too surprisingly, it's being led by Amazon--yet another big-name tech contender working to get in on the evolution of healthcare via technology. Google, along with other big IT names such as IBM, Salesforce and Siemens, are all in the midst of trying to secure a profitable spot in next-gen healthcare.
Sanofi's new CEO, Olivier Brandicourt, warned union workers in June that for the company to grow its French manufacturing operations, they needed to get more efficient, but he didn't say by how much. They need to improve a lot, it turns out.
In this week's EuroBiotech Report, after four weeks in which drug pricing emerged as the go-to political football in the U.S. and economic issues rocked markets, Shield Therapeutics' confidence in its ability to pull off a smooth IPO has waned, prompting the specialty pharma to hit pause on its plans. The big question now is how quickly the situation will settle down. And more.
Evgen Pharma has rebooted its IPO plans months after abandoning an attempt to raise £20 million ($30 million) on the London Stock Exchange. The aim now is to tap investors for £5 million, a sum that will support Phase II trials of Evgen's vegetable-inspired drug in breast cancer and stroke.
Shield Therapeutics picked a bad time to try to go public. Since it unveiled its plans on September 7, the NASDAQ Biotechnology Index has slumped 10% and confidence on the London Stock Exchange has seesawed as well. Faced with such conditions, Shield has decided to postpone its listing in London.
The European Medicines Agency has put Cell Therapy's Heartcel on its conditional approval pathway, raising the possibility that the allogeneic stem cell therapy could come to market in 2017. And with the drug now nearing the market, Cell Therapy has begun to sound out investors about an IPO.
Euroscreen has topped up its bank balance to support the globalization of its clinical trial program. The €16 million ($18 million) round will allow the G-protein coupled receptor specialist to file an IND and advance ongoing Phase II trials of its lead candidate in women's health diseases.
Shares in DBV Technologies traded up as much as 13% in Paris following the publication of long-term data from a trial of its peanut allergy treatment. The open-label extension to a Phase IIb trial found that the extra year of taking Viaskin Peanut was associated with a rise in the proportion of kids who responded to the treatment.
Pfizer announced plans to sell a plant in India that was slated to be shuttered. But another Pfizer facility in Ireland that was once on the chopping block has not only been taken off the list of facilities no longer needed but is adding several dozen jobs.
In this week's EuroBiotech Report, having been rejected by AbbVie, Galapagos hit the gas on its partnering strategy. Several potential partners are already giving the data the once-over, potentially putting Galapagos in a position to meet its goal of having a new deal in place by the end of the year. And more.